Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2024 Nov 29;14(12):9796–9804. doi: 10.21037/qims-24-1260

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2024 AME Publishing Company. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

FDG PET/CT scan showing hypermetabolic activity in the breast, lung, and thyroid. (A) PET image of the breast metastasis. (B) CT image of the breast metastasis. (C) Fused PET/CT image of the breast metastasis. (D) Whole-body PET MIP image showing lung metastasis and breast metastasis. (E) Fused PET/CT image of the thyroid recurrence. FDG PET/CT revealed a hypermetabolic nodule (2.8 cm × 2.0 cm) with SUV_max of 7.08 in the upper internal quadrant of the left breast [red arrows in (A), (B), (C), and (D)], along with hypermetabolic nodules in the right lower lung [black arrow in (D)] and the thyroid gland [white arrow in (E)]. FDG, fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; SUV_max, maximum standardized uptake value; MIP, maximum intensity projection.